Skip to content

Emphysema procedures and lung transplantation

TL;DR — Lung-volume reduction targets hyperinflation rather than airflow obstruction alone. Surgical volume reduction and bronchoscopic one-way valves can improve function and quality of life in selected severe emphysema, but selection determines benefit and harm (Shah 2017, PMID 27693408). Valve benefit requires a target lobe with little collateral ventilation; pneumothorax is a major early risk (Criner 2018, PMID 29787288). Bullectomy is distinct, treating a giant compressive bulla. Transplant can improve survival or quality of life in advanced disease, but donor scarcity, frailty, cancer, infection and comorbidity constrain candidacy. Every procedural pathway begins after optimized inhaled therapy, smoking abstinence and pulmonary rehabilitation.

Why volume reduction works

Emphysematous destruction reduces elastic recoil and causes expiratory flow limitation, gas trapping and hyperinflation. Removing or collapsing the worst tissue can improve diaphragm geometry and allow better lung to operate at a more efficient volume (Welling 2023, PMID 37039738).

Procedure Target Mechanism Signature risk
Bullectomy Giant bulla compressing adjacent lung Remove nonfunctional air space Air leak
LVRS Selected emphysematous regions Resect tissue, reduce hyperinflation Perioperative morbidity/mortality
Endobronchial valves Target lobe without collateral ventilation Induce lobar atelectasis Pneumothorax
Coils/vapor/other BLVR Selected investigational phenotypes Remodel or ablate target Device-specific irreversible injury
Lung transplant End-stage diffuse disease Replace diseased lung(s) Rejection, infection, mortality

Selection work-up

Domain Required question
Symptoms/function Severe limitation despite optimized therapy and PR?
Physiology Hyperinflation sufficient to explain limitation?
CT Heterogeneous target, fissure integrity, bulla, cancer?
Gas exchange Hypoxemia/hypercapnia and procedural risk?
Exercise Reserve and risk profile?
Comorbidity Cardiac, frailty, infection, pulmonary hypertension?
Behavior/support Smoking abstinence, adherence, follow-up capacity?

CT defines emphysema distribution and potential targets; it is not a stand-alone eligibility test (Newell 2002, PMID 11813818).

Lung-volume-reduction surgery

LVRS provides the most direct reduction but carries operative risk. Benefit is not uniform: emphysema distribution, exercise capacity and surgical risk interact. Reviews emphasize multidisciplinary selection in experienced centers (Garner 2020, PMID 32434233).

Favorable feature Unfavorable feature
Severe hyperinflation Limited hyperinflation
Heterogeneous/upper-lobe target Diffuse disease without target
Rehabilitation completed Active smoking or severe frailty
Acceptable cardiac reserve Prohibitive comorbidity
Symptoms despite optimized care Symptoms explained mainly by another disease

Endobronchial valves

Valves permit air and secretions to leave while preventing inspiratory entry, collapsing the treated lobe. Collateral ventilation across incomplete fissures prevents atelectasis and benefit (Eberhardt 2018, PMID 29105909).

LIBERATE randomized selected heterogeneous emphysema with little/no collateral ventilation and found improved FEV1, exercise and health status after Zephyr valves; pneumothorax clustered early (Criner 2018, PMID 29787288).

Valve pathway step Failure mode
Quantitative CT target No dominant damaged lobe
Fissure/collateral ventilation assessment Air bypass prevents collapse
Bronchoscopy and complete lobar occlusion Migration, granulation, incomplete seal
Early monitored period Pneumothorax
Long-term follow-up Infection, loss of effect, reintervention

Systematic reviews position valves as established for a narrow selected phenotype, not generalized severe COPD (Koster 2022, PMID 35562097; Podder 2024, PMID 39025124).

Bullectomy

A giant bulla can compress relatively preserved lung and mimic diffuse hyperinflation. Bullectomy is most rational when imaging demonstrates compression, symptoms are substantial and remaining lung has usable reserve. Diffuse emphysema without a compressive bulla is a different problem.

Transplantation

Referral precedes listing. Timing balances death risk without transplant against procedural and lifelong immunosuppression risk. Evaluation integrates BODE-like risk, exacerbations, hypercapnia, pulmonary hypertension, functional trajectory and quality of life.

Phase Key issues
Referral Advanced progressive disease despite maximal therapy
Evaluation Cancer screening, infection, cardiac/renal status, frailty
Listing Expected survival benefit, urgency and donor allocation
Operation Single versus bilateral strategy
Follow-up Rejection, infection, malignancy, renal/metabolic toxicity

Choosing among procedures

Procedures are not a ladder. A patient may be anatomically suited to valves but not LVRS, or vice versa; transplant may be inappropriate because of age/comorbidity despite severe symptoms. Multidisciplinary review should compare expected gain, early hazard, durability and the option value of later transplant (Shah 2017, PMID 27693408).

Comparative effect sizes

Intervention/evidence Quantitative result Selection lesson
NETT overall 1,218 participants; mortality 0.11 death/person-year in both LVRS and medical arms (RR 1.01, P=0.90); >10-W exercise improvement at 24 months in 15% versus 3% (Fishman 2003, PMID 12759479). Average survival neutrality concealed strong qualitative interaction.
NETT upper-lobe/low exercise subgroup Mortality RR 0.47, P=0.005 with LVRS (Fishman 2003, PMID 12759479). Anatomy plus functional reserve identified benefit.
NETT non-upper-lobe/high exercise subgroup Mortality RR 2.06, P=0.02 with LVRS (Fishman 2003, PMID 12759479). Procedure can harm a poorly selected phenotype.
TRANSFORM valves ≥12% FEV1 response at 3 months in 55.4% versus 6.5%; 6-month differences: residual volume −700 mL, 6MWD +78.7 m, SGRQ −6.5 points (Kemp 2017, PMID 28885054). Absence of collateral ventilation is essential.
TRANSFORM safety Pneumothorax in 19/65 treated participants (29.2%) (Kemp 2017, PMID 28885054). Early post-procedure observation and rescue expertise are part of efficacy delivery.

LIBERATE replicated clinically important valve effects in heterogeneous emphysema without collateral ventilation and confirmed pneumothorax as a major early harm (Criner 2018, PMID 29787288). Valve and LVRS evidence should not be compared by headline FEV1 change alone because eligibility, procedural risk, durability and rescue options differ.

Selection matrix

Feature LVRS Endobronchial valves Transplant
Target Resect diseased hyperinflated lung Lobar atelectasis without collateral ventilation Replace end-stage lungs
Strongest signal Upper-lobe disease, low exercise capacity after PR (Fishman 2003, PMID 12759479) Intact fissure/negative collateral ventilation (Kemp 2017, PMID 28885054) Survival/quality tradeoff after maximal therapy (Perch 2022, PMID 36050206)
Early dominant harm Operative mortality, prolonged air leak Pneumothorax Primary graft dysfunction, infection, rejection
Durability threat Progression in remaining lung Valve migration, granulation, re-aeration Chronic allograft dysfunction
Reversibility No Device removable, but complications can be serious No

Transplant evidence boundary

Transplantation can produce large functional gains but randomized survival comparison is unavailable. Registry reports provide the most complete outcome context and are subject to donor allocation, center practice and selection (Perch 2022, PMID 36050206). BODE predicts mortality better than FEV1 alone (Celli 2004, PMID 14999112), yet transplant timing also depends on exacerbations, hypercapnia, pulmonary hypertension, frailty, malignancy risk and expected waiting-list versus post-transplant survival.

Indirect comparisons and post-transplant evidence

A network meta-analysis highlights both the promise and limitation of device comparisons. In heterogeneous emphysema without collateral ventilation, Spiration and Zephyr valves improved FEV1 by 0.11 L (95% CI 0.05–0.16) and 0.14 L (0.08–0.19) and SGRQ by −9.32 and −8.14 points versus control; only Zephyr significantly improved walking distance (52.3 m, 26.5–77.9) (Iftikhar 2020, PMID 32574516). In mixed homogeneous/heterogeneous populations, the estimated walking gain was 56.7 m (23.7–89.8) for Zephyr versus 30.3 m (4.0–56.6) for coils, but these are indirect comparisons and both increased procedure-related pneumothorax.

Transplant evidence answers a different question. In 3,405 UNOS recipients transplanted for COPD, 52% received induction immunosuppression; adjusted mortality was lower with induction (HR 0.793, 95% CI 0.693–0.909) and bronchiolitis-obliterans onset was delayed (subdistribution HR 0.801, 0.694–0.925) (Duffy 2016, PMID 26829054). This observational post-transplant association does not establish who should receive a scarce graft, nor can it be compared directly with valve or LVRS effects before transplant. Reviews therefore emphasize multidisciplinary selection rather than a universal procedure hierarchy (Polverino 2023, PMID 37105590).

STEP-UP provides a collateral-ventilation-independent but inflammatory procedure contrast: among 70 randomized people with upper-lobe-predominant emphysema, staged thermal vapor ablation improved relative FEV1 by 14.7% (95% CI 7.8–21.5) and SGRQ by −9.7 points (−15.7 to −3.7) at six months, while serious exacerbation occurred in 24% versus 4% and one possibly treatment-related death occurred (Herth 2016, PMID 26899390). For transplant, a 54-recipient analysis found cohort-level survival benefit only with pre-transplant BODE at least seven by year four, despite many individuals outliving BODE-predicted survival (Lahzami 2010, PMID 19996194). Small size and use of non-transplant prediction as counterfactual limit certainty.

Non-valve bronchoscopic procedures show benefit–harm tension

In the collateral-ventilation-positive subgroup of STEP-UP, thermal-vapor ablation produced a 12-month between-group FEV1 difference of 14.6% (p=0.0137); the 8.4-point SGRQ-C difference did not reach conventional significance (p=0.0712), and respiratory serious adverse events increased immediately after treatment (Gompelmann 2016, PMID 27838692). Because this was a post hoc fissure analysis of 54 participants, it is proof of mechanistic feasibility rather than a definitive alternative to valves.

RENEW randomized 315 people with severe emphysema: coils improved median 6-minute-walk change by 14.6 m over usual care—below the prespecified 25-m individual MCID—although 40.0% versus 26.9% achieved ≥25 m and SGRQ improved by 8.9 points (Sciurba 2016, PMID 27179849). The discordance between mean distance, responder rate, quality of life and major complications makes endpoint choice central to judging net benefit.

Open questions

  • CELEB randomized 88 people eligible for either approach and found no significant 12-month difference in i-BODE improvement, but complete primary outcomes were available for only 49 participants; a precise comparative selection rule remains unvalidated (Buttery 2023, PMID 36796833).
  • Which CT/physiology markers predict durable five-year valve response? (Koster 2022, PMID 35562097)
  • Can pneumothorax risk be reduced without losing lobar collapse? (Criner 2018, PMID 29787288)
  • A 20-recipient matched cohort found no significant difference in 12-month post-transplant survival after prior endoscopic lung-volume reduction, but bronchiectasis and post-transplant airway colonization were more frequent; the small single-center study leaves comparative surgical-risk estimates imprecise (Fuehner 2015, PMID 26138023).
  • Which patient-reported goals best define procedural success? (Brock 2023, PMID 37673413)

References

  1. Shah PL, et al. Lung volume reduction for emphysema. Lancet Respir Med. 2017. PMID 27693408
  2. Criner GJ, et al. LIBERATE Zephyr endobronchial-valve trial. Am J Respir Crit Care Med. 2018. PMID 29787288
  3. Welling JBA, et al. Dynamics of hyperinflation. Respirology. 2023. PMID 37039738
  4. Garner JL, et al. Lung volume reduction in pulmonary emphysema. Semin Respir Crit Care Med. 2020. PMID 32434233
  5. Koster TD, et al. Bronchoscopic lung volume reduction for emphysema: review and update. Semin Respir Crit Care Med. 2022. PMID 35562097
  6. Eberhardt R, et al. Endobronchial valve placement in emphysema. Respirology. 2018. PMID 29105909
  7. Newell JD Jr. CT of emphysema. Radiol Clin North Am. 2002. PMID 11813818
  8. Podder S, et al. Bronchoscopic lung volume reduction: a review. Semin Respir Crit Care Med. 2024. PMID 39025124
  9. Brock JM, et al. Endobronchial lung volume reduction with valves reduces exacerbations. Respir Med. 2023. PMID 37673413
  10. Fishman A, et al. LVRS versus medical therapy for severe emphysema: NETT. N Engl J Med. 2003. PMID 12759479
  11. Kemp SV, et al. TRANSFORM Zephyr endobronchial-valve trial. Am J Respir Crit Care Med. 2017. PMID 28885054
  12. Perch M, et al. ISHLT adult lung-transplantation report focused on COPD. J Heart Lung Transplant. 2022. PMID 36050206
  13. Celli BR, et al. The BODE index in COPD. N Engl J Med. 2004. PMID 14999112
  14. Fuehner T, et al. Lung transplantation after endoscopic lung volume reduction. Respiration. 2015. PMID 26138023
  15. Buttery S, et al. Lung volume reduction surgery versus endobronchial valves: a randomised controlled trial. Eur Respir J. 2023. PMID 36796833
  16. Iftikhar IH, et al. Bronchoscopic lung-volume reduction with valves and coils: a network meta-analysis. Ann Am Thorac Soc. 2020. PMID 32574516
  17. Duffy JS Jr, et al. Induction therapy for lung transplantation in COPD: analysis of the UNOS registry. COPD. 2016. PMID 26829054
  18. Polverino F, et al. Lung volume reduction in COPD: scope or surgery. Eur Respir J. 2023. PMID 37105590
  19. Herth FJ, et al. Segmental thermal-vapor ablation in severe emphysema: STEP-UP randomized trial. Lancet Respir Med. 2016. PMID 26899390
  20. Lahzami S, et al. Survival impact of lung transplantation for COPD. Eur Respir J. 2010. PMID 19996194
  21. Gompelmann D, et al. Lung volume reduction with vapor ablation in the presence of incomplete fissures: 12-month STEP-UP results. Respiration. 2016. PMID 27838692
  22. Sciurba FC, et al. Effect of endobronchial coils versus usual care on exercise tolerance in severe emphysema: the RENEW randomized trial. JAMA. 2016. PMID 27179849